EUVIMEDEUVIMED entdecken
Crossref

Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment

Zishuo Guo, Haocheng Zheng iD, Tieshan Wang iD, Ning Han iD, Haitong Zhang iD, Jialing Li iD, Xuehao Cheng iD, Jinhong Ye iD, Shouying Du iD, Pengyue Li iD

Small · 2025-01 · 21 (2)

DOI: 10.1002/smll.202405752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 15.11.2024. Verfasst von Zishuo Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing University of Chinese Medicine, Beijing, 102488, China. Hauptthemen laut MEDLINE: Immunotherapy, Nanoparticles, Drug Delivery Systems, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer has emerged as a significant threat that gravely endanger human health. Anti‐tumor immunotherapy has now emerged as an important treatment for cancer. However, immunosuppressive tumor microenvironment limits the antitumor immunity. The importance of the immune system in the cancer treatment process must be emphasized. Herein, two precision‐targeted nanoparticles PD‐L1@Cur‐NPs and PD‐1@AS‐NPs are constructed for cancer treatment. PD‐L1@Cur‐NPs can precisely target tumor cells in vivo to eradicate tumor cells or induce them apoptosis. PD‐1@AS‐NPs can precisely target T cells in vivo to activate the T cell‐mediated immune system and induce antitumor immune responses. Furthermore, these two nanoparticles have good synergistic effect and show stronger antitumor effect after combination. After treatment with the combination of two nanoparticles, the tumor volumes of C57BL/6 tumor‐bearing mice are significantly reduced. Moreover, the percentage of CD8 + T cells and CD4 + T cells in the tumor significantly increased, and the percentage of regulatory T cells significantly decreased. The percentage of memory T cells and memory effector T cells in the spleen also significantly increased after treatment, suggesting that the antitumor immunity is activated after treatment. This study provides a new antitumor treatment strategy combining chemotherapy and immunotherapy, which has good application prospect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNanoparticlesDrug Delivery SystemsNeoplasmsAntineoplastic AgentsAnimalsMice, Inbred C57BLMiceCell Line, TumorTumor MicroenvironmentHumansB7-H1 Antigen

Stichwörter der Autor:innen

cancercombination therapyimmunotherapynanodrug delivery systems

Substanzen

Antineoplastic AgentsB7-H1 Antigen

Autor:innen und Institutionen

  • Beijing University of Chinese Medicine, Beijing, 102488, China.

ORCID-Profile: Haocheng Zheng, Tieshan Wang, Ning Han, Haitong Zhang, Jialing Li, Xuehao Cheng, Jinhong Ye, Shouying Du, Pengyue Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, Z., Zheng, H., Wang, T., Han, N., Zhang, H., Li, J., Cheng, X., Ye, J., Du, S., & Li, P. (2025). Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment. Small, 21(2). https://doi.org/10.1002/smll.202405752

Vancouver

Guo Z, Zheng H, Wang T, Han N, Zhang H, Li J, et al. Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment. Small. 2025;21(2). doi:10.1002/smll.202405752

BibTeX
@article{Guo2025,
  author = {Guo, Zishuo and Zheng, Haocheng and Wang, Tieshan and Han, Ning and Zhang, Haitong and Li, Jialing and Cheng, Xuehao and Ye, Jinhong and Du, Shouying and Li, Pengyue},
  title = {Combination Nanodrug Delivery Systems Facilitate the Syncretism of Chemotherapy with Immunotherapy to Promote Cancer Treatment},
  journal = {Small},
  year = {2025},
  volume = {21},
  number = {2},
  doi = {10.1002/smll.202405752}
}
Kostenlos starten →